UK markets closed

BRAIN Biotech AG (0RFI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
7.600.00 (0.00%)
At close: 12:43PM BST
Full screen
Previous close7.60
Open7.60
Bid0.00 x 0
Ask0.00 x 0
Day's range7.60 - 7.60
52-week range7.60 - 7.60
Volume14,602
Avg. volumeN/A
Market cap137.495M
Beta (5Y monthly)1.44
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    BRAIN Biotech publishes first ESG and Sustainability Report

    DGAP-News: BRAIN Biotech AG / Key word(s): SustainabilityBRAIN Biotech publishes first ESG and Sustainability Report 20.06.2022 / 08:00 The issuer is solely responsible for the content of this announcement.BRAIN Biotech publishes first ESG and Sustainability ReportZwingenberg, June 20, 2022 – BRAIN Biotech AG has published its first ESG and sustainability report. The company, which already directly addresses at least five UN Sustainable Development Goals (SDGs) with its products and solutions, s

  • EQS Group

    BRAIN Biotech AG: Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasons

    DGAP-News: BRAIN Biotech AG / Key word(s): PersonnelBRAIN Biotech AG: Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasons 30.05.2022 / 09:00 The issuer is solely responsible for the content of this announcement.Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasonsZwingenberg, 30.05.2022 – Professor Dr. Bernhard Hauer has informed the Chairman of the Supervisory Board of BRAIN Biotech AG that he wishes to resign from his

  • EQS Group

    BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting

    DGAP-News: BRAIN Biotech AG / Key word(s): Half Year Results/Half Year ReportBRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting 30.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting Very positive growth trend confirmed by 20% organic expansion in Q2 Significant improvement in profitability, adjusted EBITDA positive Full fiscal year